Muévete conCiencia: Exercise and Mind-Body Program for University Students
NCT07443904, Not applicable, Not yet recruiting, Universidad San Sebastián
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Muévete conCiencia: Exercise and Mind-Body Program for University Students | ClinicalTrials.gov |
| NCT number | NCT07443904 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 297 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universidad San Sebastián | ClinicalTrials.gov |
| Conditions | Healthy, Healthy Adult Participants | ClinicalTrials.gov |
| Interventions | Motor-Cognitive Dual-Task Exercise (DT), Tai Chi Mind-Body Exercise (TC), Cognitive Stimulation (CS) | ClinicalTrials.gov |
| First posted | 2026-03-02 | ClinicalTrials.gov |
| Last updated | 2026-07-24 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Working memory | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Working memory will be assessed using the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Digit Span subtest (total raw score). Scores range from 0 to 48. Higher scores indicate better working memory performance. | ClinicalTrials.gov |
| Primary | Inhibitory Control | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Inhibitory control will be assessed using the Stroop Color and Word Test. Performance will be recorded as the number of correctly completed items within the standard time limit. Scores range from 0 to 100. Higher scores indicate better inhibitory control. | ClinicalTrials.gov |
| Primary | Cognitive Flexibility | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention) | Trail Making Test Parts A and B (TMT) using normative data for the Latin American Spanish-speaking adult population. The TMT assesses the ability to alternate between mental sets and manage divided attention demands. The score is the completion time for each part of the TMT-A (Minimum = 0; maximum = 100) and TMT-B (Minimum = 0; maximum = 300). Lower completion time indicates better performance. | ClinicalTrials.gov |
| Secondary | Physiological Stress Salivary Cortisol | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Salivary cortisol levels reflect physiological stress associated with hypothalamic-pituitary-adrenal (HPA) axis activity. Changes in physiological stress in response to the interventions will be assessed non-invasively through salivary cortisol determination using a competitive ELISA assay. Cortisol concentrations will be expressed in µg/dL. The analytical measurement range of the assay is approximately 0.012-3.0 µg/dL. Higher values indicate greater physiological stress. | ClinicalTrials.gov |
| Secondary | Depression, anxiety, and Stress symptoms | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Symptoms of depression, anxiety, and stress will be assessed using the Depression Anxiety Stress Scales (DASS-21). The scale consists of 21 items rated on a Likert scale from 0 ("did not apply to me at all") to 5 ("applied to me very much or most of the time"), reflecting the extent to which each statement describes the participant's experiences over the previous week (Minimum = 0; maximum = 126). Higher scores indicate more global symptoms. The DASS-21 is a brief self-report measure with well-established psychometric properties in university student populations. | ClinicalTrials.gov |
| Secondary | Academic stress | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Academic Stress Scale (Barraza-Macías) - 33-item self-report instrument assessing academic stressors, coping strategies, and stress-related physical, psychological, and behavioral reactions. the total score range Minimum = 33; maximum = 165. Higher scores indicate more global symptoms. | ClinicalTrials.gov |
| Secondary | Physical Activity | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Physical activity will be assessed using the International Physical Activity Questionnaire - Short Form (IPAQ-SF). Physical activity will be expressed as MET-minutes per week depending on reported activity. Higher scores indicate higher levels of physical activity. | ClinicalTrials.gov |
| Secondary | Muscle Strength | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Muscle strength will be measured using handgrip dynamometry. Three trials will be performed for each hand, and the highest value will be recorded in kilograms-force (kg/f). Higher values indicate greater muscle strength. | ClinicalTrials.gov |
| Secondary | Body Weight | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Body weight will be assessed using bioelectrical impedance analysis and expressed in kilograms (kg). Higher values indicate greater body weight. | ClinicalTrials.gov |
| Secondary | Height | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Height will be measured in meters (m) using a standardized stadiometer or wall-mounted measuring tape, with participants standing upright without shoes. Higher values indicate greater height. | ClinicalTrials.gov |
| Secondary | Body Fat Percentage | Baseline (pre-intervention) and immediately after completion of the 12-week intervention (post-intervention). | Body fat percentage will be assessed using bioelectrical impedance analysis and expressed as percentage of total body mass (%). Higher values indicate greater adiposity and poorer body composition. | ClinicalTrials.gov |
| Other | Intervention adherence | Throughout the 12-week intervention period | Intervention adherence will be assessed by recording attendance at the scheduled intervention sessions. A participation rate will be calculated as the percentage of attended sessions relative to the total number of planned sessions (attendance/24 sessions × 100). Higher percentages indicate greater adherence to the intervention. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.